Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fcγ receptor II (CD32)

@inproceedings{Werwitzke2008TreatmentOL,
  title={Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fcγ receptor II (CD32)},
  author={Sonja Werwitzke and D Trick and Peter Sondermann and Kenji Kamino and Brigitte Schlegelberger and Katja Kniesch and Andreas Tiede and Uwe Jacob and Reinhold Ernst Schmidt and Torsten Witte},
  year={2008}
}
Objectives: Systemic lupus erythematosus (SLE) is a classical autoimmune disorder characterised by the production of IgG autoantibodies against double-stranded DNA (dsDNA). Activation of FcγR-bearing effector cells by immune complexes (ICs) is a key event in SLE pathogenesis as lupus-prone NZB/NZW F 1 hybrids lacking activating Fcγ receptors (FcγR) are protected against inflammatory kidney damage despite glomerular deposition of ICs. Moreover, soluble FcγRs inhibit IC-caused Arthus reaction in… CONTINUE READING

Similar Papers

Topics from this paper.